Skip to main
We’re doing some system maintenance
  1. /
  2. Stocks
  3. /
  4. Clarus Therapeutics Holdings
CRXT

Buy CRXT Stock

CRXT
See CRXT stock price and Buy/Sell Clarus Therapeutics Holdings with any amount of money. Discuss news and analysts' price predictions with the investor community.
Sign up to start investing
CRXT

Clarus Therapeutics Holdings (CRXT)

We couldn’t load this chart.

Some stock charts might currently not be supported. To try again, please refresh this page.

About Clarus Therapeutics Holdings (CRXT)

Clarus Therapeutics Holdings, Inc. is a pharmaceutical company, which engages in developing androgen and metabolic therapies for men and women, including potential therapies for orphan indications. The company was founded in 2004 and is headquartered in Northbrook, IL.
Market Cap
$1.55M
1 Year High
$8
Volume
1 Year Low
$0.02
Price to Earnings Ratio
Open
Dividend Rate
High
Dividend Yield
Low

Community

People who own or watch CRXT stock

CRXT Stock Rating

What analysts recommend for CRXT stock, on a scale from 1(buy) to 5(sell).
Buy2.3 / 5
BuyHoldSell

CRXT Stock Earnings

The value each CRXT share was expected to gain vs. the value that each CRXT share actually gained.
Expected
Actual

CRXT Stock News

Frequently Asked Questions (FAQ)

As of Sep 26, 2022, the market cap for CRXT stock is $1.55M

The 52-week high for CRXT stock is $8. The current CRXT stock price $0 is 100.00% below its 52-week high

The 52-week low for CRXT stock is $0.02. The current CRXT stock price $0 has increased 100.00% from its 52-week low

No, the CRXT stock does not pay dividends to its shareholders

The target price for CRXT stock is $2.25 based on the average of what a group of analyst think CRXT stock could be worth at a future date. This is not a prediction by Public.com

Buy CRXT Stock

CRXT
See CRXT stock price and Buy/Sell Clarus Therapeutics Holdings with any amount of money. Discuss news and analysts' price predictions with the investor community.
Sign up to start investing

Community

People who own or watch CRXT stock
  • skenotrading avatar
  • chrissykemp avatar
  • KellyPage avatar
  • 592 avatar
  • aegrix avatar
Check the background of this firm on FINRA’s BrokerCheck.

© Copyright 2022 Public Holdings, Inc. All Rights Reserved.

Market data powered by Xignite.

Securities are offered to self-directed customers by Open to the Public Investing, Inc. (“Open to the Public Investing”), a registered broker-dealer and member of FINRA & SIPC. Additional information about your broker can be found by clicking here. Open to Public Investing is a wholly-owned subsidiary of Public Holdings Inc. (“Public Holdings”). This is not an offer, solicitation of an offer or advice to buy or sell securities, or open a brokerage account in any jurisdiction where Open to the Public Investing is not registered. Securities products offered by Open to the Public Investing are not FDIC insured.

Cryptocurrency execution and custody services are provided by Apex Crypto LLC (NMLS ID 1828849) through a software licensing agreement between Apex Crypto LLC and Public Crypto LLC. Apex Crypto is not a registered broker-dealer or a member of SIPC or FINRA. Cryptocurrencies are not securities and are not FDIC or SIPC insured. Apex Crypto is licensed to engage in virtual currency business activity by the New York State Department of Financial Services. Please ensure that you fully understand the risks involved before trading: Legal Disclosures

Commission-free trading of stocks and ETFs refers to $0 commissions for Open to the Public Investing self-directed individual cash brokerage accounts that trade the U.S. listed securities electronically. Keep in mind, that other fees such as regulatory fees, Premium subscription fees, wire transfer fees, and paper statement fees may apply to your brokerage account. Please see Open to the Public Investing’s Fee Schedule to learn more.

All investments involve the risk of loss and the past performance of a security or a financial product does not guarantee future results or returns.